NASDAQ:AUTL Autolus Therapeutics (AUTL) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free AUTL Stock Alerts $6.20 +0.38 (+6.52%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$5.80▼$6.2650-Day Range$5.39▼$7.2952-Week Range$1.61▼$7.45Volume1.26 million shsAverage Volume1.75 million shsMarket Capitalization$1.44 billionP/E RatioN/ADividend YieldN/APrice Target$7.76 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Autolus Therapeutics alerts: Email Address Autolus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside28.3% Upside$7.96 Price TargetShort InterestHealthy1.19% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 25 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.85) to ($0.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.45 out of 5 starsMedical Sector317th out of 947 stocksBiological Products, Except Diagnostic Industry44th out of 159 stocks 3.4 Analyst's Opinion Consensus RatingAutolus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.96, Autolus Therapeutics has a forecasted upside of 28.3% from its current price of $6.21.Amount of Analyst CoverageAutolus Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.19% of the outstanding shares of Autolus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Autolus Therapeutics has recently decreased by 10.65%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUTL. Previous Next 2.4 News and Social Media Coverage News SentimentAutolus Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Autolus Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows5 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.78% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.85) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -5.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -5.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Autolus Therapeutics Stock (NASDAQ:AUTL)Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.Read More AUTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUTL Stock News HeadlinesMarch 18, 2024 | markets.businessinsider.comBreaking Down Autolus Therapeutics: 4 Analysts Share Their ViewsMarch 17, 2024 | finance.yahoo.comAutolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call TranscriptMarch 18, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Autolus Therapeutics Amid Strong Progress and Potential of Obe-celMarch 15, 2024 | finance.yahoo.comQ4 2023 Autolus Therapeutics PLC Earnings CallMarch 15, 2024 | finance.yahoo.comAutolus Therapeutics Full Year 2023 Earnings: EPS Misses ExpectationsMarch 15, 2024 | finanznachrichten.deAutolus Therapeutics plc: Autolus Therapeutics Reports Full Year 2023 Financial Results and Business UpdatesMarch 15, 2024 | msn.comAutolus Therapeutics FY 2023 Earnings PreviewMarch 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL)March 14, 2024 | finance.yahoo.comAutolus Therapeutics PLC Reports Full Year 2023 Financial ResultsMarch 14, 2024 | seekingalpha.comAutolus Therapeutics plc 2023 Q4 - Results - Earnings Call PresentationMarch 14, 2024 | msn.comAutolus Therapeutics GAAP EPS of -$1.20 misses by $0.10, revenue of $1.69M misses by $0.01MMarch 14, 2024 | globenewswire.comAutolus Therapeutics Reports Full Year 2023 Financial Results and Business UpdatesMarch 13, 2024 | benzinga.comAutolus Therapeutics's Earnings OutlookMarch 13, 2024 | americanbankingnews.comAutolus Therapeutics plc (NASDAQ:AUTL) Given Average Rating of "Moderate Buy" by BrokeragesMarch 12, 2024 | globenewswire.comAutolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing siteMarch 11, 2024 | finance.yahoo.comAutolus Therapeutics announces publication in Blood Cancer JournalMarch 9, 2024 | finance.yahoo.comAUTL Jun 2024 10.000 callMarch 1, 2024 | ca.finance.yahoo.comAUTL Mar 2024 2.500 callFebruary 29, 2024 | globenewswire.comAutolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024February 29, 2024 | uk.investing.comAutolus Therapeutics Ltd (AUTL)February 25, 2024 | edition.cnn.comVaxcyte, Inc.February 24, 2024 | msn.comAutolus Therapeutics plc - Depositary Receipt () (AUTL) Price Target Increased by 5.27% to 9.86February 23, 2024 | benzinga.comAutolus Therapeutics Stock (NASDAQ:AUTL), Analyst Ratings, Price Targets, PredictionsFebruary 23, 2024 | benzinga.comAutolus Therapeutics Stock (NASDAQ:AUTL), Quotes and News SummaryFebruary 22, 2024 | finance.yahoo.comAutolus Therapeutics announces publication in Nature CommunicationsSee More Headlines Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today3/18/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AUTL CUSIPN/A CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees399Year FoundedN/APrice Target and Rating Average Stock Price Target$7.96 High Stock Price Target$10.00 Low Stock Price Target$4.80 Potential Upside/Downside+25.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-148,840,000.00 Net MarginsN/A Pretax Margin-3,180.50% Return on Equity-92.37% Return on Assets-47.47% Debt Debt-to-Equity RatioN/A Current Ratio8.21 Quick Ratio8.21 Sales & Book Value Annual Sales$1.70 million Price / Sales847.79 Cash FlowN/A Price / Cash FlowN/A Book Value$1.73 per share Price / Book3.59Miscellaneous Outstanding Shares232,270,000Free Float172,577,000Market Cap$1.44 billion OptionableOptionable Beta1.90 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Christian Martin Itin Ph.D. (Age 60)CEO & Director Comp: $2.73MDr. Martin Pule M.D. (Age 52)MBBS, Founder, Senior VP & Chief Scientific Officer Mr. Christopher Vann (Age 59)Senior VP & COO Mr. David Brochu (Age 68)Senior VP & Chief Technical Officer Mr. Brent Rice (Age 58)Senior VP, Chief Commercial Officer & Site Head of US Dr. Edgar E. W. Braendle M.D. (Age 64)Ph.D., Senior VP & Chief Development Officer Mr. Robert F. Dolski (Age 54)Chief Financial Officer Ms. Olivia ManserDirector of Investor RelationsDr. Chris Williams (Age 44)Senior Vice President of Corporate Development Mr. Alexander SwanChief Human Resources OfficerMore ExecutivesKey CompetitorsRelay TherapeuticsNASDAQ:RLAYCARGO TherapeuticsNASDAQ:CRGXScholar RockNASDAQ:SRRKADMA BiologicsNASDAQ:ADMA4D Molecular TherapeuticsNASDAQ:FDMTView All CompetitorsInstitutional OwnershipGoldman Sachs Group Inc.Bought 64,910 shares on 3/1/2024Ownership: 0.076%Perceptive Advisors LLCBought 1,831,167 shares on 2/26/2024Ownership: 1.053%Sierra Summit Advisors LLCBought 42,744 shares on 2/22/2024Ownership: 0.025%Price T Rowe Associates Inc. MDBought 3,001,208 shares on 2/16/2024Ownership: 1.725%Citadel Advisors LLCBought 3,300 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions AUTL Stock Analysis - Frequently Asked Questions Should I buy or sell Autolus Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AUTL shares. View AUTL analyst ratings or view top-rated stocks. What is Autolus Therapeutics' stock price target for 2024? 6 Wall Street analysts have issued 1 year price targets for Autolus Therapeutics' shares. Their AUTL share price targets range from $4.80 to $10.00. On average, they anticipate the company's share price to reach $7.96 in the next year. This suggests a possible upside of 28.3% from the stock's current price. View analysts price targets for AUTL or view top-rated stocks among Wall Street analysts. How have AUTL shares performed in 2024? Autolus Therapeutics' stock was trading at $6.44 at the beginning of the year. Since then, AUTL shares have decreased by 3.6% and is now trading at $6.2050. View the best growth stocks for 2024 here. Are investors shorting Autolus Therapeutics? Autolus Therapeutics saw a drop in short interest in the month of February. As of February 29th, there was short interest totaling 2,770,000 shares, a drop of 10.6% from the February 14th total of 3,100,000 shares. Based on an average daily trading volume, of 1,650,000 shares, the short-interest ratio is presently 1.7 days. View Autolus Therapeutics' Short Interest. When is Autolus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our AUTL earnings forecast. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics plc (NASDAQ:AUTL) released its earnings results on Tuesday, November, 2nd. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.04. The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.25 million. During the same quarter last year, the company earned ($0.72) EPS. What ETF holds Autolus Therapeutics' stock? Range Cancer Therapeutics ETF holds 44,025 shares of AUTL stock, representing 1.33% of its portfolio. What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA), TG Therapeutics (TGTX), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP) and Advanced Micro Devices (AMD). When did Autolus Therapeutics IPO? (AUTL) raised $125 million in an IPO on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. Who are Autolus Therapeutics' major shareholders? Autolus Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include TFG Asset Management GP Ltd (4.60%), Armistice Capital LLC (2.21%), Price T Rowe Associates Inc. MD (1.73%), Price T Rowe Associates Inc. MD (1.73%), Perpetual Ltd (1.19%) and Perceptive Advisors LLC (1.05%). How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AUTL) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetryThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.